MedTrace Logo

Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients

NCT06473259 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2024-06-25

No results posted yet for this study

Summary

The aim of this observational study is to evaluate the clinical outcomes of treatment with docetaxel, ARTA (alone or in combination) or with radiotherapy on the primary tumor for mCSPC, in an unselected population, in clinical practice

Conditions

Interventions

DRUG

Docetaxel

6 courses of docetaxel 75 mg/sqm iv

DRUG

Apalutamide Oral Tablet

240 mg /daily orally

DRUG

Enzalutamide Oral Tablet

600 mg /daily orally

DRUG

Abiraterone acetate tablets

1000 mg /daily orally

DRUG

Darolutamide Oral Tablet

600 mg/daily orally

RADIATION

radiotherapy

radical radiotherapy on primary tumor

DRUG

Triptorelin

3,75 mg im/4 w

Sponsors & Collaborators

  • Santa Chiara Hospital

    lead OTHER

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-16
Primary Completion
2026-12-31
Completion
2028-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06473259 on ClinicalTrials.gov